☰

Cliff Berkman - Publications

Affiliations: 
Chemistry Washington State University, Pullman, WA, United States 
Tree Info Similar researchers PubMed Report error

56 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Backer BS, Choy CJ, Davis AL, Browne ZS, Berkman CE. Tunable pH-Sensitive 2-Carboxybenzyl Phosphoramidate Cleavable Linkers. Tetrahedron Letters. 61. PMID 32205898 DOI: 10.1016/J.Tetlet.2020.151650  0.722
2019 Olatunji FP, Kesic BN, Choy CJ, Berkman CE. Phosphoramidate derivates as controlled-release prodrugs of l-Dopa. Bioorganic & Medicinal Chemistry Letters. PMID 31400939 DOI: 10.1016/J.Bmcl.2019.08.005  0.711
2019 Ling X, Latoche JD, Choy CJ, Kurland BF, Laymon CM, Wu Y, Salamacha N, Shen D, Geruntho JJ, Rigatti LH, Windish HP, Langton-Webster B, Berkman CE, Anderson CJ. Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 31321650 DOI: 10.1007/S11307-019-01404-8  0.812
2019 White DS, Choy CJ, Moural TW, Martin SE, Wang J, Gargaro S, Kang C, Berkman CE. Bis(benzoyl) phosphate inactivators of beta-lactamase C from Mtb. Bioorganic & Medicinal Chemistry Letters. PMID 31281019 DOI: 10.1016/J.Bmcl.2019.07.002  0.734
2019 Moural TW, White DS, Choy CJ, Kang C, Berkman CE. Crystal Structure of Phosphoserine BlaC from Inactivated by Bis(Benzoyl) Phosphate. International Journal of Molecular Sciences. 20. PMID 31269656 DOI: 10.3390/Ijms20133247  0.71
2018 Behr SC, Aggarwal R, Van Brocklin HF, Flavell RR, Geo K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, ... ... Berkman CE, et al. First-in-Human Phase I study of CTT1057, a Novel F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 30464040 DOI: 10.2967/Jnumed.118.220715  0.377
2017 Choy CJ, Ling X, Geruntho JJ, Beyer SK, Latoche JD, Langton-Webster B, Anderson CJ, Berkman CE. (177)Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice. Theranostics. 7: 1928-1939. PMID 28638478 DOI: 10.7150/Thno.18719  0.812
2017 Ziaei P, Geruntho JJ, Marin-Flores OG, Berkman CE, Grant Norton M. Silica nanostructured platform for affinity capture of tumor-derived exosomes Journal of Materials Science. 52: 6907-6916. DOI: 10.1007/S10853-017-0905-0  0.415
2016 Choy CJ, Ley CR, Davis AL, Backer BS, Geruntho JJ, Clowers BH, Berkman CE. Second-Generation of Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release. Bioconjugate Chemistry. PMID 27562353 DOI: 10.1021/Acs.Bioconjchem.6B00422  0.725
2016 Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, et al. Structure-Activity Relationship of 18F-labeled phosphoramidate peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-targeted inhibitor analogues for PET imaging of prostate cancer. Journal of Medicinal Chemistry. PMID 27228467 DOI: 10.1021/Acs.Jmedchem.5B01850  0.822
2016 Choy CJ, Geruntho JJ, Davis AL, Berkman CE. A Tunable pH-Sensitive Linker for Controlled Release. Bioconjugate Chemistry. PMID 26886721 DOI: 10.1021/acs.bioconjchem.6b00027  0.723
2016 Choy CJ, Berkman CE. A method to determine the mode of binding for GCPII inhibitors using bio-layer interferometry. Journal of Enzyme Inhibition and Medicinal Chemistry. 1-4. PMID 26873576 DOI: 10.3109/14756366.2015.1132208  0.74
2016 Whalley E, Berkman C, Vanbrocklin H, Langton-Webster B. Development and safety of a novel, irreversibly-binding PSMA-targeted prostate cancer radiodiagnostic. Journal of Clinical Oncology. 34: 11568-11568. DOI: 10.1200/Jco.2016.34.15_Suppl.11568  0.433
2015 Nedrow JR, Latoche JD, Day KE, Modi J, Ganguly T, Zeng D, Kurland BF, Berkman CE, Anderson CJ. Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer. Molecular Imaging and Biology : Mib : the Official Publication of the Academy of Molecular Imaging. PMID 26552656 DOI: 10.1007/S11307-015-0908-7  0.643
2015 Novakova Z, Cerny J, Choy CJ, Nedrow J, Choi JK, Lubkowski J, Berkman CE, Barinka C. Design of composite inhibitors targeting glutamate carboxypeptidase II: the importance of effector functionalities. The Febs Journal. PMID 26460595 DOI: 10.1111/Febs.13557  0.742
2015 Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, VanBrocklin HF, Berkman CE. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nuclear Medicine and Biology. PMID 26169882 DOI: 10.1016/J.Nucmedbio.2015.06.003  0.659
2015 Ley CR, Beattie NR, Dannoon S, Regan M, VanBrocklin H, Berkman CE. Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry Letters. 25: 2536-9. PMID 25956413 DOI: 10.1016/J.Bmcl.2015.04.047  0.475
2014 Martin SE, Ganguly T, Munske GR, Fulton MD, Hopkins MR, Berkman CE, Black ME. Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. Bioconjugate Chemistry. 25: 1752-60. PMID 25157916 DOI: 10.1021/Bc500362N  0.647
2014 Wu LY, Johnson JM, Simmons JK, Mendes DE, Geruntho JJ, Liu T, Dirksen WP, Rosol TJ, Davis WC, Berkman CE. Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells. The Prostate. 74: 451-7. PMID 24449207 DOI: 10.1002/Pros.22727  0.661
2014 Liu T, Mendes DE, Berkman CE. Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells. International Journal of Oncology. 44: 918-22. PMID 24424840 DOI: 10.3892/Ijo.2014.2256  0.411
2014 Liu T, Mendes DE, Berkman CE. Prolonged androgen deprivation leads to overexpression of calpain 2: implications for prostate cancer progression. International Journal of Oncology. 44: 467-72. PMID 24297527 DOI: 10.3892/Ijo.2013.2196  0.391
2013 Liu T, Mendes DE, Berkman CE. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. International Journal of Oncology. 43: 1125-30. PMID 23877345 DOI: 10.3892/Ijo.2013.2020  0.334
2013 Choy CJ, Fulton MD, Davis AL, Hopkins M, Choi JK, Anderson MO, Berkman CE. Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors. Chemical Biology & Drug Design. 82: 612-9. PMID 23773397 DOI: 10.1111/Cbdd.12174  0.768
2013 Kasten BB, Liu T, Nedrow-Byers JR, Benny PD, Berkman CE. Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorganic & Medicinal Chemistry Letters. 23: 565-8. PMID 23232055 DOI: 10.1016/J.Bmcl.2012.11.015  0.818
2013 Nedrow-Byers JR, Moore AL, Ganguly T, Hopkins MR, Fulton MD, Benny PD, Berkman CE. PSMA-targeted SPECT agents: mode of binding effect on in vitro performance. The Prostate. 73: 355-62. PMID 22911263 DOI: 10.1002/Pros.22575  0.8
2012 Liu T, Wu LY, Fulton MD, Johnson JM, Berkman CE. Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. International Journal of Oncology. 41: 2087-92. PMID 23041906 DOI: 10.3892/Ijo.2012.1649  0.644
2012 Nedrow-Byers JR, Jabbes M, Jewett C, Ganguly T, He H, Liu T, Benny P, Bryan JN, Berkman CE. A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent. The Prostate. 72: 904-12. PMID 22670265 DOI: 10.1002/Pros.21493  0.818
2012 Liu T, Nedrow-Byers JR, Hopkins MR, Wu LY, Lee J, Reilly PT, Berkman CE. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate. Bioorganic & Medicinal Chemistry Letters. 22: 3931-4. PMID 22607680 DOI: 10.1016/J.Bmcl.2012.04.110  0.819
2012 Wu LY, Liu T, Hopkins MR, Davis WC, Berkman CE. Chemoaffinity capture of pre-targeted prostate cancer cells with magnetic beads. The Prostate. 72: 1532-41. PMID 22488169 DOI: 10.1002/Pros.22508  0.651
2012 Wu LY, Abernathy DE, Liu T, Van Wie BJ, Davis WC, Berkman CE. Abstract C40: Large-scale isolation of prostate cancer cells by combining leukapheresis and elutriation with chemoaffinity capture Cancer Research. 72: C40-C40. DOI: 10.1158/1538-7445.Prca2012-C40  0.648
2011 Ganguly T, Kasten BB, Buar DK, MacGillivray LR, Berkman CE, Benny PD. The hydrazide/hydrazone click reaction as a biomolecule labeling strategy for M(CO) 3 (M = Re, 99mTc) radiopharmaceuticals Chemical Communications. 47: 12846-12848. PMID 22044929 DOI: 10.1039/C1Cc15451F  0.439
2011 Liu T, Nedrow-Byers JR, Hopkins MR, Berkman CE. Spacer length effects on in vitro imaging and surface accessibility of fluorescent inhibitors of prostate specific membrane antigen. Bioorganic & Medicinal Chemistry Letters. 21: 7013-6. PMID 22018464 DOI: 10.1016/J.Bmcl.2011.09.115  0.826
2011 Liu C, Pan J, Li S, Zhao Y, Wu LY, Berkman CE, Whorton AR, Xian M. Capture and visualization of hydrogen sulfide by a fluorescent probe. Angewandte Chemie (International Ed. in English). 50: 10327-9. PMID 21898737 DOI: 10.1002/Anie.201104305  0.49
2011 Liu T, Jabbes M, Nedrow-Byers JR, Wu LY, Bryan JN, Berkman CE. Detection of prostate-specific membrane antigen on HUVECs in response to breast tumor-conditioned medium. International Journal of Oncology. 38: 1349-55. PMID 21331445 DOI: 10.3892/Ijo.2011.946  0.789
2011 Blank BR, Alayoglu P, Engen W, Choi JK, Berkman CE, Anderson MO. N-substituted glutamyl sulfonamides as inhibitors of glutamate carboxypeptidase II (GCP2). Chemical Biology & Drug Design. 77: 241-7. PMID 21219587 DOI: 10.1111/J.1747-0285.2011.01085.X  0.359
2011 Wu LY, Liu T, Grimm AL, Davis WC, Berkman CE. Flow cytometric detection of prostate tumor cells using chemoaffinity labels. The Prostate. 71: 52-61. PMID 20632319 DOI: 10.1002/Pros.21221  0.619
2010 Liu T, Wu LY, Hopkins MR, Choi JK, Berkman CE. A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorganic & Medicinal Chemistry Letters. 20: 7124-6. PMID 20947349 DOI: 10.1016/J.Bmcl.2010.09.057  0.675
2010 Liu T, Wu LY, Berkman CE. Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Letters. 296: 106-12. PMID 20452720 DOI: 10.1016/J.Canlet.2010.04.003  0.64
2010 Liu T, Wu LY, Choi JK, Berkman CE. Targeted photodynamic therapy for prostate cancer: inducing apoptosis via activation of the caspase-8/-3 cascade pathway. International Journal of Oncology. 36: 777-84. PMID 20198319 DOI: 10.3892/Ijo_00000553  0.664
2010 Yao V, Berkman CE, Choi JK, O'Keefe DS, Bacich DJ. Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. The Prostate. 70: 305-16. PMID 19830782 DOI: 10.1002/Pros.21065  0.41
2010 Wu LY, Choi JK, Hatton KY, Berkman CE. A simple method for the oxidation of α-amino acid esters to α-oximino esters Tetrahedron Letters. 51: 402-403. DOI: 10.1016/J.Tetlet.2009.11.045  0.545
2009 Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu T, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 50: 2042-8. PMID 19910433 DOI: 10.2967/Jnumed.109.066589  0.808
2009 Liu T, Wu LY, Choi JK, Berkman CE. In vitro targeted photodynamic therapy with a pyropheophorbide--a conjugated inhibitor of prostate-specific membrane antigen. The Prostate. 69: 585-94. PMID 19142895 DOI: 10.1002/Pros.20909  0.682
2008 Liu T, Toriyabe Y, Kazak M, Berkman CE. Pseudoirreversible inhibition of prostate-specific membrane antigen by phosphoramidate peptidomimetics. Biochemistry. 47: 12658-60. PMID 18983168 DOI: 10.1021/Bi801883V  0.393
2008 Liu T, Wu LY, Kazak M, Berkman CE. Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. The Prostate. 68: 955-64. PMID 18361407 DOI: 10.1002/Pros.20753  0.677
2008 Wu LY, Do JC, Kazak M, Page H, Toriyabe Y, Anderson MO, Berkman CE. Phosphoramidate derivatives of hydroxysteroids as inhibitors of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry Letters. 18: 281-4. PMID 18023582 DOI: 10.1016/J.Bmcl.2007.10.096  0.667
2007 Wu LY, Anderson MO, Toriyabe Y, Maung J, Campbell TY, Tajon C, Kazak M, Moser J, Berkman CE. The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry. 15: 7434-43. PMID 17869524 DOI: 10.1016/J.Bmc.2007.07.028  0.62
2007 Anderson MO, Wu LY, Santiago NM, Moser JM, Rowley JA, Bolstad ES, Berkman CE. Substrate specificity of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry. 15: 6678-86. PMID 17764959 DOI: 10.1016/J.Bmc.2007.08.006  0.577
2006 Liu T, Toriyabe Y, Berkman CE. Purification of prostate-specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expression and Purification. 49: 251-5. PMID 16815035 DOI: 10.1016/J.Pep.2006.05.008  0.365
2006 Wone DW, Rowley JA, Garofalo AW, Berkman CE. Optimizing phenylethylphosphonamidates for the inhibition of prostate-specific membrane antigen. Bioorganic & Medicinal Chemistry. 14: 67-76. PMID 16154750 DOI: 10.1016/J.Bmc.2005.07.056  0.35
2005 Wu LY, Berkman CE. Synthesis of N-phosphoryl amino acids using bis(9-fluorenylmethyl)phosphite Tetrahedron Letters. 46: 5301-5303. DOI: 10.1016/J.Tetlet.2005.06.022  0.48
2004 Mallari JP, Choy CJ, Hu Y, Martinez AR, Hosaka M, Toriyabe Y, Maung J, Blecha JE, Pavkovic SF, Berkman CE. Stereoselective inhibition of glutamate carboxypeptidase by organophosphorus derivatives of glutamic acid. Bioorganic & Medicinal Chemistry. 12: 6011-20. PMID 15498677 DOI: 10.1016/J.Bmc.2004.08.016  0.723
2004 Maung J, Mallari JP, Girtsman TA, Wu LY, Rowley JA, Santiago NM, Brunelle AN, Berkman CE. Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates. Bioorganic & Medicinal Chemistry. 12: 4969-79. PMID 15336276 DOI: 10.1016/J.Bmc.2004.06.031  0.597
2004 Maung J, Mallari JP, Choy CJ, Berkman CE. Alternatives to 1-H-tetrazole in the preparation of phosphonate diesters and phosphonamidates from phosphonyl dichlorides Tetrahedron Letters. 45: 6497-6499. DOI: 10.1016/J.Tetlet.2004.06.083  0.695
2002 Kamga I, Ng R, Hosaka M, Berkman CE. High-performance liquid chromatography method for detecting prostate-specific membrane antigen activity. Analytical Biochemistry. 310: 125-7. PMID 12413483 DOI: 10.1016/S0003-2697(02)00284-1  0.305
2001 Lu H, Hu Y, Choy CJ, Mallari JP, Villanueva AF, Arrozal AF, Berkman CE. Synthesis of individual glutamate-containing phosphonamidothionate stereoisomers Tetrahedron Letters. 42: 4313-4316. DOI: 10.1016/S0040-4039(01)00746-8  0.72
Show low-probability matches.